Search

Your search keyword '"Luzardo Henriquez, Hugo Daniel"' showing total 11 results
Start Over Author "Luzardo Henriquez, Hugo Daniel"
11 results on '"Luzardo Henriquez, Hugo Daniel"'

1. Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets

Author

Gonzalez Barca, Eva, primary, Tomás‐Roca, Laura, additional, Esteve, Anna, additional, Rodriguez, Marta, additional, Gato, Lucía, additional, Alonso‐Alonso, Ruth, additional, Martin Garcia‐Sancho, Alejandro, additional, Cordoba, Raul, additional, Monter‐Rovira, Anna, additional, Bastos‐Oreiro, Mariana, additional, Bergua Burgues, Juan Miguel, additional, Sayas, Maria Jose, additional, Viguria Alegria, Maria Cruz, additional, Sanchez‐Blanco, Jose Javier, additional, Roig Pellicer, Monica, additional, Luzardo Henriquez, Hugo Daniel, additional, de Oña, Raquel, additional, Cabezudo, Maria Elena, additional, Infante, Maria Stefania, additional, Queizán Hernández, José Antonio, additional, Sanz‐Pamplona, Rebeca, additional, Blanco, Oscar, additional, Mozos, Ana, additional, Climent, Fina, additional, and Piris, Miguel Angel, additional

Published
2023
Full Text
View/download PDF

2. Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Author

Iacoboni, Gloria, primary, Iraola-Truchuelo, Josu, additional, Mussetti, Alberto, additional, Fernández-Caldas, Paula, additional, Navarro Garcés, Víctor, additional, Martin Lopez, ANA Africa, additional, Delgado, Javier, additional, Pérez Martínez, Ariadna, additional, Guerreiro, Manuel, additional, Caballero Gonzalez, Ana Carolina Carolina, additional, Martínez-Cibrián, Nuria, additional, Luzardo Henriquez, Hugo Daniel, additional, Sanchez, Jose M., additional, Sancho, Juan-Manuel, additional, Barba, Pere, additional, Kwon, Mi, additional, Corral, Lucía López, additional, Hernani, Rafael, additional, Reguera, Juan Luis, additional, Sureda, Anna, additional, Martín García-Sancho, Alejandro, additional, Bastos-Oreiro, Mariana, additional, and Abrisqueta, Pau, additional

Published
2022
Full Text
View/download PDF

3. Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)

Author

Martín Moro, Fernando, primary, Bento De Miguel, Leyre, additional, Marquet Palomanes, Juan, additional, Gutierrez, Antonio, additional, Diaz-Lopez, Antonio, additional, Sanchez, Jose M., additional, Garcia Vela, Jose Antonio, additional, Salar, Antonio, additional, Cordoba, Raul, additional, Novelli, Silvana, additional, Rodriguez-Salazar, Maria J., additional, González de Villambrosia, Sonia, additional, Del Campo, Raquel, additional, Luzardo Henriquez, Hugo Daniel, additional, Garcia, Daniel, additional, Sancho, Juan-Manuel, additional, Abrisqueta, Pau, additional, Martín García-Sancho, Alejandro, additional, and Bastos-Oreiro, Mariana, additional

Published
2022
Full Text
View/download PDF

4. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Author

Bastos-Oreiro, Mariana, primary, Jimenez-Ubieto, Ana, additional, González de Villambrosia, Sonia, additional, Cordoba, Raul, additional, Pérez Ceballos, Elena, additional, Martin, EVA Maria DONATO, additional, Muntañola Prat, Ana, additional, Luzardo Henriquez, Hugo Daniel, additional, Escoda, Lourdes, additional, Peñarrubia, Maria Jesús, additional, Pozas, María, additional, Lopez-Garcia, Alberto, additional, Garcia, Daniel, additional, Pardal, Emilia, additional, Salazar Lozada, Claudia, additional, and Martín García-Sancho, Alejandro, additional

Published
2022
Full Text
View/download PDF

5. Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Author

Bastos-Oreiro, Mariana, primary, Gutierrez, Antonio, additional, Reguera, Juan Luis, additional, Iacoboni, Gloria, additional, Corral, Lucía López, additional, Terol, María José, additional, Ortiz-Maldonado, Valentín, additional, Sanz, Jaime, additional, Guerra, Luisa Maria, additional, Mussetti, Alberto, additional, Abrisqueta Costa, Pau, additional, Delgado Serrano, Javier, additional, Hernani, Rafael, additional, Luzardo Henriquez, Hugo Daniel, additional, Sancho, Juan-Manuel, additional, Montalban, Carlos, additional, Salar, Antonio, additional, Grande, Carlos, additional, Bento, Leyre, additional, González de Villambrosia, Sonia, additional, Garcia, Daniel, additional, Herrero, Blanca, additional, Martínez-Cibrian, Nuria, additional, Sureda, Anna, additional, Perez-Martinez, Antonio, additional, Barba, Pere, additional, Kwon, Mi, additional, and Martin Garcia-Sancho, Alejandro, additional

Published
2021
Full Text
View/download PDF

6. New Prognosis Score Including Absolute Lymphocytes/Monocytes Ratio and Beta2microglobulin in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Author

Bento, Leyre, primary, Diaz-Lopez, Antonio, additional, Barranco, Gilberto Israel, additional, Martin Moreno, Ana Maria, additional, Baile, Monica, additional, Martín, Alejandro, additional, Sancho, Juan Manuel, additional, Garcia, Olga, additional, Rodríguez, Mario, additional, Sánchez-Pina, José María, additional, Novelli, Silvana, additional, Salar, Antonio, additional, Bastos, Mariana, additional, Rodriguez-Salazar, Maria J., additional, González de Villambrosia, Sonia, additional, Cordoba, Raul, additional, Garcia Recio, Marta, additional, Martínez-Serra, Jordi, additional, Del Campo, Raquel, additional, Luzardo Henriquez, Hugo Daniel, additional, García, Daniel, additional, Hong, Azueg, additional, Abrisqueta, Pau, additional, Rodriguez, Jose, additional, and Gutiérrez, Antonio, additional

Published
2018
Full Text
View/download PDF

7. Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Author

González-Barca, Eva, primary, Martín, Alejandro, additional, Bello, Jose Luis, additional, Bergua Burgues, Juan Miguel Miguel, additional, Panizo, Carlos, additional, Encuentra, Maite, additional, Monter Rovira, Ana, additional, Cordoba, Raul, additional, Bastos, Mariana, additional, Sanchez Blanco, Jose Javier, additional, Gomez, Pilar, additional, Marin Niebla, Ana, additional, González de Villambrosia, Sonia, additional, Sayas, Maria Jose, additional, Luzardo Henriquez, Hugo Daniel, additional, Viguria Alegria, Maria De La Cruz, additional, Sanchez-Gonzalez, Blanca, additional, Roig, Monica, additional, Perez De Oteyza, Jaime, additional, Cabezudo, Elena, additional, Escoda, Lourdes, additional, de Oña, Raquel, additional, Queizan, Josë Antonio, additional, Infante, Maria Stefania, additional, Muntañola Prat, Ana, additional, and Lopez, Andres, additional

Published
2018
Full Text
View/download PDF

8. Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Author

Bastos-Oreiro, Mariana, Abrisqueta Costa, Pau, Gutierrez, Antonio, Jimenez Ubieto, Ana, Pozas, Maria, Gonzalez De Villambrosia, Sonia, Cordoba, Raul, Lopez Garcia, Alberto, Perez Ceballos, Elena, Navarro, Belen, Muntanola, Ana, Donato, Eva, Diez-baeza, Eva, Escoda Teigell, Maria Lourdes, Luzardo Henriquez, Hugo Daniel, Peñarrubia-Ponce, María, Garcia Belmonte, Daniel, Pardal, Emilia, Lozada, Claudia, Lopez-Guillermo, Armando, and Martín García-Sancho, Alejandro

Abstract

Introduction:Several new therapeutic agents have been approved in recent years for the treatment of relapsed/refractory (R/R) Large B cell lymphoma (LBCL) (diffuse large B cell lymphoma [DLBCL] and high-grade B cell lymphomas [HGBCL]), such as new monoclonal antibodies (MA), bispecific antibodies (BA) and CAR-T cell therapy. The objective of our study was to evaluate the epidemiology and the use of these new therapies (NT) in Spain and to analyze the impact on survival.

Published
2023
Full Text
View/download PDF

9. Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Author

Bailen, Rebeca, Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Lopez Corral, Lucia, Hernani, Rafael, Ortiz-Maldonado, Valentin, Guerreiro, Manuel, Caballero Gonzalez, Ana Carolina, Guerra, Luisa, Sanchez Pina, Jose Maria, Mussetti, Alberto, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Catalá, Eva, Delgado Serrano, Javier, Luzardo Henriquez, Hugo Daniel, Caballer, Jaime Sanz, Calbacho, Maria, Carpio, Cecilia, Ribera, Josep-Maria, Torrent, Anna, Sureda Balari, Anna Maria, Briones, Javier, Hernandez Boluda, Juan Carlos, Martinez-Cibrian, Nuria, Martin Garcia-Sancho, Alejandro, and Barba, Pere

Abstract

Background: Median age at diagnosis of diffuse large B cell lymphoma (DLBCL) patients is 66 years; 40% of patients are diagnosed at an age greater than 70 years. CAR-T cell therapy is approved for the treatment of relapsed/refractory DLBCL patients; however, a deeper understanding of outcomes in patients older than 70 years is needed. Our aim was to analyze outcomes of CAR-T cell therapy in this population and compare them to those obtained in younger patients in the real-world setting.

Published
2023
Full Text
View/download PDF

10. Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Author

Marin Niebla, Ana, Bastos-Oreiro, Mariana, Cabirta Touzón, Alba, Canelo Vilaseca, Marta, Sancho, Juan-Manuel, Jimenez Ubieto, Ana, Sáez Marín, Adolfo Jesús, Garcia Noblejas, Ana, Prieto Martinez, Pablo, Nicolas, Concepcion, Grande Garcia, Carlos, Luzardo Henriquez, Hugo Daniel, Hernandez Rivas, Jose Angel, Muntanola, Ana, Alonso Trillo, Rosalia, Arnaiz, Irene, Donato, Eva, Villafuerte Gutierrez, Paola, Garcia Belmonte, Daniel, Roldan Perez, Alicia, Suarez Ordonez, Sandra, Navarro Garces, Víctor, Bosch, Francesc, and Abrisqueta, Pau

Abstract

Background:MCL remains incurable and its management is highly heterogeneous due to the lack of standard treatment. Since the results from prospective clinical trials are not always reproducible in real-life patients, the aim of this study was to analyze the management in clinical practice of patients with MCL in Spain and its impact on their survival.

Published
2023
Full Text
View/download PDF

11. The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Author

Iacoboni, Gloria, Navarro Garces, Victor, Iraola, Josu, Sesques, Pierre, Rejeski, Kai, Serpenti, Fabio, Bastos-Oreiro, Mariana, Martin Lopez, ANA Africa, Delgado, Javier, Perez, Ariadna, Guerreiro, Manuel, Caballero Gonzalez, Ana Carolina, Martinez-Cibrian, Nuria, Luzardo Henriquez, Hugo Daniel, Sanchez Pina, Jose Maria, Sancho, Juan-Manuel, Ghesquieres, Herve, Mussetti, Alberto, Barba, Pere, Lopez Corral, Lucia, Hernani, Rafael, Reguera, Juan Luis, Sureda Balari, Anna Maria, Bosch, Francesc, Martin Garcia-Sancho, Alejandro, Kwon, Mi, Kuhnl, Andrea, Subklewe, Marion, Bachy, Emmanuel, Villacampa, Guillermo, and Abrisqueta Costa, Pau

Abstract

Introduction:Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients in the third or later line setting. There is no standard treatment after CAR T-cell therapy progression and a wide range of outcomes are observed in this patient population. Besides the interval between CAR T-cell infusion and progressive disease (PD), data regarding prognostic factors at time of progression are scarce. Our aim was to develop a new prognostic tool to predict overall survival (OS) after CAR T-cell therapy progression with easily-available markers from routine clinical practice.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results